Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: A prospective clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1187-1193

  Higham, C E ^a   Atkinson, A B ^b   Aylwin, S ^c   Bidlingmaier, M ^d   Drake, W M ^e   Lewis, A ^b   Martin, N M ^f   Moyes, V ^e   Newell Price, J ^g   Trainer, Peter J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANGIOPEPTIN; CABERGOLINE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCOSE METABOLISM; HUMAN; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; TREATMENT DURATION; UNITED KINGDOM;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; GREAT BRITAIN; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PATIENT DROPOUTS; RECEPTORS, SOMATOTROPIN;

EID: 84859550807     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2603     Document Type: Article

References (30)

1. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759 (Pubitemid 33152999)
2. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ; German Pegvisomant Investigators 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82
3. Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ 2009 Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 71:86-91
4. Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 161:21-25
5. Jehle S, Reyes CM, Sundeen RE, Freda PU 2005 Alternate day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 90:1588-1593 (Pubitemid 40464023)
6. Parkinson C, Burman P, Messig M, Trainer PJ 2007 Gender, body weight, disease activity and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190-195 (Pubitemid 46067530)
7. Trainer PJ 2009 ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19-S24
8. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378 (Pubitemid 28496509)
9. Moyes VJ, Metcalfe KA, Drake WM 2008 Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol 159:541-545
10. Sandret L, Maison P, Chanson P 2011 Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96:1327-1335
11. Cozzi R, Attanasio R, Lodrini S, Lasio G 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-215 (Pubitemid 39093116)
12. Selvarajah D, Webster J, Ross R, Newell-Price J 2005 Effectiveness of addingdopamineagonisttherapytolong-actingsomatostatinanaloguesin the management of acromegaly. Eur J Endocrinol 152:569-574
13. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov HJ 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
14. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X,Webb SM, van der Lely AJ 2008 Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:3853-3859
15. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646 (Pubitemid 40693415)
16. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ 2009 A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71:549-557
17. Webb SM, Badia X, Surinach NL: Spanish AcroQOL Study Group 2006 Validity and clinical applicability of the acromegaly quality of life questionnaire. AcroQol: a 6-month prospective study. Eur J Endocrinol 155:269-277
18. Elmlinger MW, Kühnel W, Weber MM, Ranke MB 2004 Reference ranges for two automated chemiluminescent assays for serum insulin- like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654-664 (Pubitemid 38979144)
19. Roemmler J, Bidlingmaier M, Schopohl J 2010 Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant. Pituitary 13:89-93
20. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF 1999 Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84:2098-2103 (Pubitemid 30647040)
21. Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ 2001 Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab 86:590-593 (Pubitemid 32207463)
22. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM 2009 Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 94:1255-1263
23. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K 2008 Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721-4727
24. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38 (Pubitemid 46041751)
25. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46 (Pubitemid 46041752)
26. Ørskov H, Frystyk J, Nielsen C, Hansen AT, Weeke J, Jørgensen JO 2007 Concomitant, specific determination of growth hormone and pegvisomant in human serum. Growth Horm IGF Res 17:431-434 (Pubitemid 47324308)
27. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, AfsharF,SabinI, Jenkins JP,ChewSL,MonsonJP, BesserGM,Grossman AB 2001 Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645-1652 (Pubitemid 32374917)
28. Feenstra J, de HerderWW,ten Have SM, van den BeldAW,Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646 (Pubitemid 40693415)
29. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ 2009 Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160:529-533
30. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ 2006 Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154:805-806 (Pubitemid 43997717)